Company news

Ultragenyx Pharmaceutical Inc. news in 2021

Ultragenyx Pharmaceutical Inc.'s news releases, calls and decks from 2021, newest first.

View company

Ultragenyx Announces First Patient Dosed in Phase 1/2 Clinical Study of UX053, an mRNA Therapy for the Treatment of Glycogen Storage Disease Type III

November 30, 2021

GeneTx and Ultragenyx Announce Presentations at Upcoming 2021 FAST Global Summit & Gala

November 30, 2021

Ultragenyx to Present at Evercore 4th Annual HealthconX Conference

November 28, 2021

Ultragenyx Announces Additional Positive Multi-Year Durability Data from Phase 1/2 AAV Gene Therapy Studies

November 28, 2021

Ultragenyx Reports Third Quarter 2021 Financial Results and Corporate Update

November 1, 2021

Ultragenyx to Host Conference Call for Third Quarter 2021 Financial Results and Corporate Update

October 25, 2021

Ultragenyx to Present at Jefferies Gene Therapy/Editing Summit

October 24, 2021

Ultragenyx Initiates Cyprus2+, a Pivotal Clinical Trial Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease

October 17, 2021

GeneTx and Ultragenyx Announce First Patient Dosed in Canada in Phase 1/2 Clinical Trial of GTX-102 in Patients with Angelman Syndrome

October 6, 2021

Mereo BioPharma and Ultragenyx Present Data from the Phase 2b ASTEROID Study of UX143 (setrusumab) in Osteogenesis Imperfecta (OI) at the American Society for Bone and Mineral Research (ASBMR) 2021 Annual Meeting

September 30, 2021

Ultragenyx Announces Crysvita® (burosumab) and UX143 (setrusumab) Data Presentations at Upcoming American Society for Bone and Mineral Research (ASBMR) 2021 Annual Meeting

September 26, 2021

GeneTx and Ultragenyx Announce FDA has Removed Clinical Hold on Phase 1/2 Clinical Study of GTX-102 for the Treatment of Angelman Syndrome in the U.S.

September 26, 2021

MEDIA ADVISORY: Ultragenyx Announces Mepsevii® (vestronidase alfa) Receives Reimbursement Approval for Treatment of Mucopolysaccharidosis VII in Italy

September 8, 2021

MEDIA ADVISORY: Ultragenyx Canada Announces Health Canada Approval of a Second Indication for Crysvita™ (Burosumab Injection) for the Treatment of Tumour Induced Osteomalacia in Adults

September 6, 2021

Ultragenyx Announces Approval of Dojolvi® (triheptanoin) in Brazil for the Treatment of Long-chain Fatty Acid Oxidation Disorders in Adults and Children

August 22, 2021

Ultragenyx Reports Second Quarter 2021 Financial Results and Corporate Update

August 1, 2021

Ultragenyx Receives Orphan Drug Designation from FDA and European Commission for UX053, an Investigational mRNA-therapy for the Treatment of Glycogen Storage Disease Type III

July 26, 2021

Ultragenyx Appoints Corsee Sanders, Ph.D., to Board of Directors

June 29, 2021

Ultragenyx Announces Positive Multi-Year Durability Data from Ongoing Phase 1/2 Gene Therapy Studies and Data on HeLa 3.0 Manufacturing Platform at American Society of Gene & Cell Therapy 2021 Annual Meeting

May 13, 2021

Ultragenyx Reports First Quarter 2021 Financial Results and Corporate Update

May 3, 2021

Ultragenyx Announces Upcoming Data Presentations at American Society of Gene & Cell Therapy 2021 Virtual Annual Meeting

April 26, 2021

Ultragenyx Completes Successful End-of-Phase 2 Meeting with FDA and Finalizes Phase 3 Study Design for DTX301 Ornithine Transcarbamylase (OTC) Gene Therapy Program

April 21, 2021

Ultragenyx Announces FDA Clearance of Investigational New Drug (IND) Application for UX053, an mRNA for the Treatment of Glycogen Storage Disease Type III

March 7, 2021

Ultragenyx Announces Approval of Dojolvi™ (UX007/triheptanoin) in Canada for the Treatment of Long-chain Fatty Acid Oxidation Disorders in Adults and Children

February 16, 2021

Ultragenyx Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Update

February 10, 2021

Ultragenyx Announces FDA Clearance of Investigational New Drug (IND) Application for UX701, a New Gene Therapy for the Treatment of Wilson Disease

January 20, 2021

Ultragenyx Reports Preliminary 2020 Revenue and 2021 Revenue Guidance for Crysvita in Ultragenyx Territories

January 10, 2021

Ultragenyx Announces Progress Across Broad Gene Therapy Portfolio and Positive Longer-Term Data from Multiple Phase 1/2 Gene Therapy Studies

January 7, 2021

Calls in 2021